Medication Integration in Treatment of Comorbid Adolescent Substance Users/Attention Deficit Hyperactivity Disorder

PHASE1CompletedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

November 30, 2011

Primary Completion Date

March 31, 2014

Study Completion Date

December 31, 2014

Conditions
Attention Deficit Hyperactivity DisorderAttention Deficit Disorder
Interventions
BEHAVIORAL

MIP Protocol

We intend for MIP to be a 5-session, family-based protocol delivered during the early portion of ASU treatment. MIP will contain three elements deemed essential for integrating pharmacological interventions into outpatient behavioral treatment for youth: (1) standardized psychiatric assessment and family-focused psychoeducation about the target problem; (2) an approved medication regimen with demonstrated efficacy for comorbid populations; (3) family-based interventions for medication acceptance and coordination of psychiatric and behavioral services. MIP will incorporate research-proven interventions from each of these core areas.

Trial Locations (1)

10009

Roberto Clemente Center, New York

All Listed Sponsors
collaborator

National Institute on Drug Abuse (NIDA)

NIH

lead

The National Center on Addiction and Substance Abuse at Columbia University

OTHER

NCT01369459 - Medication Integration in Treatment of Comorbid Adolescent Substance Users/Attention Deficit Hyperactivity Disorder | Biotech Hunter | Biotech Hunter